SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

YUPELRI

TBPH·Theravance Biopharma, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially marketed (FDA approved November 2018; China NMPA approved June 2025).
Why 4/10
YUPELRI is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout; the next catalyst is Zymeworks' Q4 2026 earnings in early 2027, which is a quarterly sales update, not a binary event. ImpactScore is 4 per the rubric for an approved drug with no imminent binary catalyst.
Actionable Insight NEUTRAL

YUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.

Price Chart

Loading chart...

Executive Summary

YUPELRI (revefenacin) is an FDA-approved once-daily nebulized LAMA bronchodilator for maintenance treatment of COPD, originally developed by Theravance Biopharma (TBPH) and launched in 2018. It is the first and only approved once-daily nebulized LAMA, occupying a specific niche for patients who cannot use inhalers. In June 2025, it received China NMPA approval. Theravance Biopharma was acquired by Zymeworks Inc. (ZYME) for $17/share in cash plus a CVR, a deal that closed on September 23, 2026. TBPH was delisted and deregistered. YUPELRI is now a revenue-generating asset within Zymeworks, contributing to the company's raised 2026 guidance of $337M-$351M in total revenue. Zymeworks reported Q3 2026 earnings on November 9, 2026, with revenue of $256.5M. YUPELRI faces competition from Spiriva HandiHaler and other LAMA/LABA products, and a Phase 4 study did not show statistical superiority over tiotropium. Generic entry is protected until at least April 2039 per a patent settlement.

How It Works

YUPELRI is a long-acting muscarinic antagonist (LAMA) bronchodilator. It relaxes the airway muscles in the lungs to keep them open, making it easier to breathe. It is administered once daily via a nebulizer (a machine that turns liquid medicine into a fine mist that is inhaled through a mouthpiece or facemask). It is used for maintenance treatment of chronic obstructive pulmonary disease (COPD).

Trial Status

YUPELRI is FDA-approved for COPD maintenance treatment (2018) and China NMPA-approved (2025). Post-marketing studies include the Phase 4 PIFR-2 trial (completed January 2024) comparing YUPELRI head-to-head against Spiriva HandiHaler, which did not show a statistically significant difference on the primary endpoint. A Phase 3 trial in China (by partner Viatris) reported positive top-line results in November 2023, supporting the China approval.

The Two-Sided Case

▲ Bull Case5
YUPELRI is the first and only FDA-approved once-daily nebulized LAMA for COPD maintenance treatment, occupying a unique niche for patients who cannot use dry-powder or mist inhalers.
YUPELRI collaboration revenue grew 15% year-over-year in Q1 2026 ($17.7M), showing steady commercial momentum.
China NMPA approval was granted in June 2025, opening a large new market; Viatris handles ex-U.S. commercialization.
Zymeworks (ZYME) acquired Theravance Biopharma for $929M and retained the YUPELRI commercial organization; the drug is expected to contribute immediately accretive revenue and cash flow with a base-case mid-teens IRR.
ZYME has strong analyst support: 18 buy/strong-buy ratings vs 1 hold, mean price target $41.50 (roughly 40% upside from the Nov 9 close of $29.63).
▼ Bear Case4
YUPELRI faces entrenched competition from Spiriva HandiHaler (tiotropium), the market-leading LAMA; a Phase 4 head-to-head study (PIFR-2) failed to show a statistically significant difference on the primary endpoint of trough FEV1 at Day 85.
Generic entry is possible on or after April 23, 2039 per a patent settlement with Teva, which could eventually erode U.S. market share.
As a nebulized therapy, YUPELRI targets a narrower subset of COPD patients than dry-powder inhalers, limiting total addressable market.
Theravance Biopharma (TBPH) was acquired by Zymeworks for $17/share and delisted; former TBPH shareholders received cash plus a contingent value right (CVR) with no further public trading in the original developer.

Upcoming Catalysts

  • Zymeworks Q4 2026 / full-year 2026 earnings (early 2027) - first full quarter of YUPELRI under Zymeworks ownership
  • Potential expansion of YUPELRI label or additional geographies via Viatris partnership

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Theravance Biopharma, Inc. 8-K TBPH ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 theglobeandmail.com3 theglobeandmail.com4 morningstar.com5 sec.gov6 khon2.com7 drugstorenews.com8 ajmc.com9 markets.businessinsider.com